Abstract. Prostate cancer (PCa) is one of the most frequently diagnosed malignancy. Although there have been many advances in PCa diagnosis and therapy, the concrete mechanism remains unknown. Long non-coding RNAs (lncRNAs) are novel biomarkers associated with PCa, and their dysregulated expression is closely associated with risk stratification, diagnosis and carcinogenesis. Accumulating evidence has suggested that lncRNAs play important roles in prostate tumorigenesis through relevant pathways, such as androgen receptor interaction and PI3K/Akt. The present review systematically summarized the potential clinical utility of lncRNAs and provided a novel guide for their function in PCa.

Contents
1. Introduction
2. Key pathways dysregulated in prostate cancer by lncRNAs
3. Therapeutic potential of lncRNAs in patients with cancer
4. Conclusions

1. Introduction

Prostate cancer (PCa) is the second most common malignancy in Western countries and accounts for 10% of cancer-related deaths (1). Approximately 26,730 deaths occurred in 2017 due to PCa in the United States. The causes of this disease include age, functional testicles, and family heredity. Most cases of PCa undergo a series of processes from androgen sensitivity neoplasia to metastatic castration-resistant PCa (mCRPC), which is presently incurable. Currently available means for diagnosis depend on prostate specific antigen (PSA) and pathological biopsy. Since PSA testing was introduced, the incidence of localized PCa has increased significantly; PSA testing can predict cancer risk and treatment outcome (2). According to the literature, almost 240,000 individuals developed PCa in the United States yearly; however, <15% of these patients eventually died; mortality is largely dependent upon PSA testing and reasonable treatment of PCa at an early stage (3-6). However, serum PSA is not particular to PCa, and levels can be enhanced in benign prostatic hyperplasia (BPH) (7) and prostatitis (8) even after a digital rectal examination. Therefore, the lack of specificity limits its further development. Low specificity has caused unnecessary biopsies, thereby leading to the overtreatment of indolent cancers. Pathological biopsy is the standard in diagnosing PCa, but it is an invasive examination, which will cause hemorrhage, infection, and even blood poisoning. Hence, a novel biomarker for PCa diagnosis and therapy should is urgently needed.

RNA plays a crucial part in the regulation of gene expression and genome organization (9,10). RNA serves as a template for protein synthesis and exerts many functions (11). The current research has concluded that only 10% of the genome is made up of protein-coding genes. A large part of the genome (~70%) is actively transcribed, which indicates that noncoding RNAs (ncRNAs) account for an overwhelming percentage of the human transcriptome (Fig. 1). At the start, ncRNAs, which is viewed as ‘noisy RNAs,’ have no transcriptional function and account for almost 90% RNAs in humans (12). ncRNAs can be divided into two major groups according to their sizes, as follows: Long (lncRNA, >200 bp) and small ncRNAs (<200 bp) (13). Small ncRNAs include termini-associated short, transcription initiation, splice site, and antisense termini-associated short RNAs (14). Most lncRNAs are generated similar to other mRNAs, as emphasized by RNA polymerase II activity and histone modifications associated with transcription initiation and elongation (15). lncRNAs can be divided into intragenic and intergenic lncRNAs according to their locations in the genome relative to protein coding.
genes (16). IncRNAs also play a role as decoys for transcription factors (17) and regulate protein activity (18,19). IncRNAs are aberrantly expressed in a several human diseases, including kidney cancer (20), colorectal cancer (21), endometrial cancer (22), testicular cancer (23,24), breast cancer (25), and hematological cancers (26,27). Bussemakers (28) first found DD3\(^\text{PC,AS}\), which is a IncRNA and is a potential diagnostic biomarker for PCa in 1999. This discovery started the research on the involvement of IncRNAs in PCa. We summarized the viewpoints, as follows (Fig. 1).

2. Key pathways dysregulated in prostate cancer by IncRNAs

Androgen receptor (AR) interaction. The AR, as a protein coding gene, is situated on the X chromosome, is approximately 110 kD and made up of four functional regions, namely, (1) the hinge region, (2) ligand-binding domain, (3) N-terminal transactivation domain, and (4) DNA-binding domain (29-31). The AR is a nuclear transcription factor required for normal prostate development and PCa; thus, it plays key roles in PCa initiation and progression (32,33). PCa undergoes progression from androgen-sensitive to resistance to castration. Androgen deprivation therapy (ADT) is the frontline treatment for PCa at the late stages. However, after 12 to 24 months of androgen deprivation, PCa will eventually progress to the lethal form of the disease known as castration-resistant PCa (CRPC), which is eventually fatal for patients with PCa. The reactivation of the AR is central to the progression of CRPC, and treatment mechanisms may also be mediated by the AR signaling axis. AR-dependent resistance mechanisms include AR enhancement, AR single-base substitution, changed intratumoral androgen biosynthesis, and the expression of constitutively active AR splice variants (34-37). IncRNAs can function as oncogenic and tumor suppressor in PCa through AR signaling axis (Table 1).

**PCGEM1.** PCGEM1, as the earliest prostate-specific IncRNA, is located on chromosome 2q32 and overexpressed in nearly 84% of patients with PCa. Recent studies revealed the PRNCR1 binding site to AR 549-623 location and the PCGEM1 combining site to the N-terminal location of AR. PCGEM1 and PRNCR1 interact with AR (38) in a recently published report. In various PCa cells, IncRNA cannot be detected in AR-null cell lines, such as DU145 and PC3 (39,40). The coalition of PRNCR1 and AR leads to enrichment of DOTIL methyltransferase methylating AR and allows the subsequent interaction of PCGEM1 with the methylated AR. In turn, PCGEM1 recruits PYGO2 (Pygopus 2), thereby allowing the binding of AR to H3K4me3 chromatin marks to the promoter regions of AR-regulated genes and leading to their activation (38).

A positive correlation of PCGEM1 with AR3, which is one of the most important splice variants that play a key role in castration resistance, was observed (41-43). This AD-PCGEM1-AR3 axis can explain several reasons why the effectiveness of ADT can only be sustained for a short time. Heterogeneous nuclear ribonucleoprotein A1 (HnRNP A1) and U2AF65, as splicing factors, play key roles in AR3 expression. When HnRNP A1 combines with PCGEM1, the coalition activity of HnRNP A1 to AR pre-mRNA is weakened. By contrast, the binding activity of U2AF65 to AR pre-mRNA is enhanced. A specific molecular mechanism does not explain why interaction between U2AF65 and PCGEM1 is dominant. The binding of PCGEM1 to U2AF65 is more competitive than that of HnRNP A1 to AR pre-mRNA (44).

**HOX transcript antisense RNA (HOTAIR).** HOTAIR IncRNA is a 2.2 kb-long transcript and overexpressed in a variety of cancer types, such as breast cancer, colorectal cancer, lung cancer, and pancreatic cancer (45-48). HOTAIR is sensitive to androgen and inhibited by androgen severely, and its expression inhibits AR ubiquitination and avoids AR protein degradation (49). HOTAIR IncRNA is entirely abolished after AR target gene is knocked down via RNA interference (49). Zhang et al (49) concluded that HOTAIR overexpression enhances aggressivity in PCa and upregulates in enzalutamide-resistant PCa cells. Therefore, attention should be paid to HOTAIR as a potential therapy target in enzalutamide-resistant patients with PCa in the future.

**C-Terminal binding protein 1 antisense (CTBP1-AS)** C-terminal binding protein 1 antisense (CTBP1-AS), which is situated in the AS region of C-terminal binding protein 1 (CTBP1), is related to AR signaling pathway and is overexpressed in both local PCa patients and metastatic PCa patients, but not in Benign Prostatic Hyperplasia (BPH). It is recruited to AR-binding sites. The CTBP1-AS IncRNA directly inhibited the expression of CTBP1 (50), which acted as the corepressor of AR by recruiting the RNA binding transcriptional repressor PTB-associated splicing factor and histone deacetylases. Thus, CTBP1-AS can enhance AR transcriptional activity. Takayama et al (51) have reported that upregulation of CTBP1-AS and downregulation of CTBP1 in PCa. CTBP1-AS knockdown inhibited cell proliferation in hormone-depleted condition in both cell lines; in contrast, CTBP1-AS overexpression induced tumor growth after castration (51).

**PCa gene 3 (PCA3).** PCA3 is a IncRNA that was initially named as DD3 and is located on chromosome 9q21-22 in antisense direction within the intron 6 of the Prune homolog 2 gene (PRUNE2 or BMCC1) (52). PCA3 is overexpressed in PCa cell lines (53,54) and modulates PCa cell survival partly according to the AR pathway, which is involved in the oncopogenesis of PCa. Meanwhile, the positive rates of its sensitivity and specificity are 82.3 and 89.0%, respectively, compared with PSA, which showed only 57.4 and 53.8% (55). Lemos et al (56) reported that PCA3 may regulate AR signal pathway through AR cofactors (57), such as ARA 54, ARA 70, CBP, and P300, when PCA3 and ERK are silenced, and Akt protein phosphorylation levels stayed the same. Thus, the preferred method should be activate AR. Both AR cofactors, including coactivators and corepressors, were upregulated, which indicated that PCA3 may be a negative modulator to AR and aberrant cofactor activity because altered or changed expression levels may be factors to the progression to mCRPC. A future potential therapy for PCa patients, especially mCRPC, is the application of PCA3.

**Phosphatidylinositol 3-kinase (PI3K)/Akt pathway.** PI3K/Akt pathway is one of the key signal transduction pathways regulating
cell proliferation. PI3K/AKT/mTOR signaling, PTEN/PI3K/AKT pathway, and PI3K/AKT/NF-kappaB/BMP-2-Smad axis play important roles in cancer progression and development (58). PI3K enzymes regulate cellular signal transduction. The PI3K/Akt pathway mainly includes PI3K activation, recruiting pleckstrin homology (PH) domain-containing proteins, phosphorylation, activating AKT, and activating necessary downstream targets (59). PI3K/Akt/mTOR is overexpressed in 30-50% of all prostate cancers (60), and its signal is regulated in PCa cellular proliferation (61), apoptosis (62), invasion, and migration (63).

**lncRNA-ATB.** lncRNA-ATB is first identified in hepatocellular carcinoma (64). Xu et al (65) reported that lncRNA-ATB is overexpressed in PCa tissues compared with normal tissues, and it is related to high PSA level, high Gleason score, and biochemical recurrence when the knockdown of lncRNA-ATB and PI3K/Akt signaling pathways is inhibited. Meanwhile, the roles of lncRNA-ATB in the invasion, migration, and tumor growth remain unclear.

**Urothelial carcinoma associated 1 (UCA1).** UCA1 is a lncRNA that is related to various cancer types (66). Ghiam et al (67) revealed that UCA1 expression is high in PCa cells when UCA1 knockdown enhances radiosensitivity in classic PCa cell lines and irradiation-resistant PCa cells due to PI3K/Akt pathway downregulation.

**LINC01296.** LINC01296 is located at chromosome 14q11.2. Wu et al (68) found that LINC01296 is upregulated in LNCaP cell lines but not in normal cell lines. Meanwhile, when silencing LINC01296, the protein expression level of PI3K-Akt-mTOR signaling pathway significantly decreased compared with that of normal cell. Therefore, the IncRNA LOC400891 regulates cell proliferation through the PI3K-Akt-mTOR signaling pathway (69).

*Act as a tumorigenesis or a tumor-inhibiting gene. Genome instability is the main factor in the promotion of cancer. The aberrant expression of lncRNAs is related to the development and progression of PCa and plays an important role in tumorigenesis or tumor-inhibiting in patients with PCa. Several lncRNAs are upregulated as oncogenes, whereas others are downregulated in cancer.*

**PCa-associated lncRNA transcripts 1 (PCAT-1).** PCAT-1, which is located in the 8q24.21 gene desert with nearly 725 kb upstream of the c-MYC oncogene (70), is overexpressed in patients with PCa (71). C-MYC protein is upregulated by PCAT-1, thereby resulting in specific gene expression programs and cell proliferation (72). When PCAT-1 is knocked down in LNCaP cells, cellular proliferation is diminished, thereby indicating that it is a potential novel biomarker for colorectal cancer metastasis.

**Second chromosome locus associated with prostate-1 (SChLAP1).** SChLAP1 is a novel biomarker that is highly upregulated in PCa (73-75) and associated with a high risk of CRPC, thereby leading to tumor cell invasion and metastasis. SChLAP1 can interfere with the SWI/SNF tumor-inhibiting complex (76) to promote tumor metastasis. SChLAP1 damages genomic binding and SNF5-mediated gene expression regulation. Similarly, Mehra et al (75) found that knocking down SChLAP1 can inhibit cell proliferation and migration in bladder cancer cell lines.

**Noncoding nuclear-enriched abundant transcript2 (NEAT2).** The IncRNA NEAT2 is 7 kb long and is also known as MALAT1. NEAT2 is highly upregulated in PCa (73-75) and associated with a high risk of CRPC, thereby leading to tumor cell invasion and metastasis. NEAT2 promotes the activation of PRC2 by connecting to the polycomb protein enhancer of zeste homolog 2 (EZH2) and enhances the EZH2-mediated inhibition of polycomb-dependent target gene E-cadherin in clear renal
cancer (84). Meanwhile, NEAT2 controls cell cycle progression by regulating the oncogenic transcription factor B-MYB (Mybl2) (85).

**H19.** The H19 gene, which is transcribed from H19/Igf2 gene cluster, is located on human chromosome 11p15.5. H19 can act as a tumor suppressor gene. Zhu et al. (86) found that the decreased H19 expression is significant in metastatic prostate cell compared with local prostate epithelial cell. Hence, H19/miR-675 axis inhibits PCa metastasis according to TGFBI downregulation.

Other genes. Double-strand DNA breaks (DSBs) are potentially lethal DNA lesions. Homologous recombination (HR) is an effective pathway for eliminating DSBs and repairing injured DNA replication forks. RAD51 is the core recombinase involved in HR, and increased RAD51 levels may cause tumorigenesis. Prensner et al (87) found that lncRNA PCAT1 is involved in the DSB repair process in PCa. TODRA is a novel IncRNA that is also known as RAD51 antisense RNA 1 and is located on 15q15.1. TODRA plays a role in RAD51 regulation. Gazy et al. (88) reported that the overexpression of TODRA causes DSB repair by HR and also enhances the fraction of RAD51 foci formed after DNA damage.

Recent studies indicated that IncRNAs can recognize miRNA elements that can be targeted by miRNAs (89). A Zebrafish model where miR-125b regulates 7sl IncRNA expression is a typical example of the miRNA-IncRNA interaction (90). Meanwhile, HOTAIR downregulation is targeted by the tumor suppressor miR-34a, thereby inhibiting CRPC cell growth (91).

### 3. Therapeutic potential of IncRNAs in patients with cancer

IncRNAs has multiple functions and high cell-type specificity. Thus, IncRNAs can provide an avenue for PCa diagnosis, prognosis, and therapy. Currently, the use of IncRNA for PCa patients is being explored.

**IncRNA targeting strategy.** The RNAi technology, which interferes with RNA expression through antisense technologies, can be widely used for the weak expression levels of IncRNAs with oncology potential (92). The key cancer-associated genes with therapeutic siRNAs have been suppressed in clinical trials.

Another method for inhibiting cancer-associated RNA is by using catalytic nucleic acids, including antisense oligonucleotides (ASOs) or by using small molecule inhibitors that can also be used to modulate IncRNAs. The small molecule inhibitors prevent the interaction of HOTAIR with LSD1 or PRC2 complexes, thereby restricting the metastatic potential of breast cancer (93).

**Targeting IncRNAs through the CRISPER/Cas system.** Currently, CRISPER/Cas (clustered regularly interspaced short palindromic repeats/CRISPER-associated system) take advantage of knocking out targeting gene for treating PCa patients. Meanwhile, Shechner et al. (94) have ever reported of using CRISPER/Cas system successfully.

### 4. Conclusions

IncRNAs are potential novel biomarkers as therapeutic targets for patients with PCa. Considering the multiple and varied processes of PCa, its treatment should be planned precisely for each patient. At the same time, when modern technology is used to kill tumors, the safety of normal tissues should be ensured. However, in spite of its advantage over other therapeutic options, many questions need to be addressed.

The biggest challenge is that further research and large-scale validation studies are imperative before the successful application to clinical trials, because the molecular mechanisms of IncRNAs and pathogenesis of PCa have not been thoroughly understood. Nevertheless, the clearer the IncRNA functions are, the better their field of therapeutic usage will be. The next challenge is that the current IncRNA marker candidates are mostly based on a small sample, and the
lack of validity limits further development. Thus, the effectiveness of IncRNA markers have to be prospectively verified in large and varied datasets. Research in animal models and clinical trials is needed to evaluate the potential side effects, including toxicity, body distribution, pharmacokinetics, and pharmacodynamics data.

Hence, IncRNAs are intriguing targets in treating patients with PCa, and their potential in therapy can be remarkable.

Acknowledgements

The authors would like to thank Miss Chen Gao (Department of Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China) for assistance.

Funding

The present study was supported by funding from Science and Technology Plan Project of Guangzhou of China (grant no. 201510010177), Medical Science and Technology Program of Guangzhou of China (grant nos. 20171A011329 and 20171A010325), Youth Scientific Research Project of Guangzhou Medical University of China (grant no. 2015A14) and Medical Research Foundation of Guangdong Province of China (grant no. A2018093).

Availability of data and materials

All data generated or analyzed during the present study are included in this article.

Authors' contributions

GJ, ZS, XL, YH, ZL and XJ conceived and designed the study. GJ and ZS wrote the manuscript. GJ, ZS, XL, YH, ZL and XJ collected the data. ZS and XJ reviewed and edited the manuscript. All authors read and approved the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Carter HB and Pearson JD: PSA velocity for the diagnosis of early prostate cancer: A new concept. Urol Clin North Am 20: 665-670, 1993.
3. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, et al: miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cεpsis. Cancer Res 69: 2287-2295, 2009.
4. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Voussen KH, Muller PA, Dotsch V, Kehrloesser S, Suyan BS, et al: Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 109: 15312-15317, 2012.
5. Gandellini P, Profumo V, Casamichelle A, Fenderico N, Borrelli S, Petrovich G, Santilli G, Callari M, Colecchia M, Pozzi S, et al: miR-205 regulates basal membrane deposition in human prostate. Implications for cancer development. Cell Death Differ 19: 1750-1760, 2012.
6. Bonci D, Coppola V, Musumeci M, Addario A, Guffridda R, Memmo L, D’Urso L, Pagliuca A, Biffoni M, Labbâye C, et al: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277, 2008.
7. Park Y, Chae JY, Kim JW, Kim JW, Oh MM, Yoon CY and Moon du G: Prostate-specific antigen mass and free prostate-specific antigen mass for predicting the prostate volume of Korean men with biopsy-proven benign prostatic hyperplasia. Korean J Urol 54: 609-614, 2013.
8. Wang Y, Hu HL, Liu ZF, Sun WZ, Chen XX and Wu CL: Diagnosis and treatment of xanthogranulomatous prostatitis: A case report and review of the literature. Zhonghua Nan Ke Xue 19: 149-152, 2013 (In Chinese).
9. ENCODE Project Consortium: An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57-74, 2012.
10. Ma W, Ay F, Lee C, Gulsog G, Deng X, Cao J, He S, Huang J, Cavanaugh C, Ware CB, Krumm A, et al: Fine-scale chromatin interaction maps reveal the cis-regulatory landscape of human lincRNA genes. Nat Methods 12: 71-78, 2015.
11. Ling H, Vincent K, Pichler M, Fosdike K, Berindei N, Neagoe I, Slack FJ and Calin GA: Junk DNA and the long non-coding RNA twist in cancer genetics. Oncogene 34: 5003-5011, 2015.
12. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, Stadler PF, Hertel J, Hackermuller J, Hofacker IL, et al: RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 316: 1484-1488, 2007.
13. Brosnan CA and Voinnet O: The long and the short of noncoding RNAs. Curr Opin Cell Biol 21: 416-425, 2009.
14. Gibb EA, Brown CJ and Lam WL: The functional role of long non-coding RNA in human carcinomas. Mol Cancer 10: 38, 2011.
15. Mercer TR and Mattick JS: Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 20: 300-307, 2013.
16. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, et al: The GENCODE v7 catalog of human long non-coding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res 22: 1775-1789, 2012.
17. Kino T, Hurt DE, Ichijo T, Nader N and Chrousos GP: Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal 3: ra8, 2010.
18. Mallory AC and Shkumatava A: IncRNAs in vertebrates: Advances and challenges. Biochimie 117: 3-14, 2015.
19. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, et al: A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 6: 308-318, 2004.
20. Seles M, Hutterer GC, Kisielch T, Pummer K, Berindan-Neagoe I, Feraakis S, Schwarzenbacher D, Stoz M, Gerger A and Pichler M: Current insights into long non-coding RNAs in renal cell carcinoma. Int J Mol Sci 17: 573, 2016.
21. Smolle M, Uranitsch S, Gerger A, Pichler M and Haybaek J: Current status of long non-coding RNAs in human cancer with specific focus on colorectal cancer. Int J Mol Sci 15: 13993-14013, 2014.
22. Smolle MA, Bullock MD, Ling H, Pichler M and Haybaek J: Long non-coding RNAs in endometrial carcinoma. Int J Mol Sci 16: 26463-26472, 2015.
23. Bezan A, Gerger A and Pichler M: MicroRNAs in testicular cancer: Implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 34: 2709-2713, 2014.
24. Ling H, Krassnig L, Bullock MD and Pichler M: MicroRNAs in testicular cancer diagnosis and prognosis. Urol Clin North Am 43: 127-134, 2016.
25. Cerò S, Schwarzenbacher A, Adiprasito JB, Stoz M, Hutterer GC, Gerger A, Ling H, Calin GA and Pichler M: Current status of long non-coding RNAs in human breast cancer. Int J Mol Sci 17: 1485, 2016.
26. Zebisch A, Hatzi S, Pichler M, Wollf A and Sill H: Therapeutic resistance in acute myeloid leukemia: The role of non-coding RNAs. Int J Mol Sci 17: 2080, 2016.

27. van der Kooi H, Friesen BE, Ling H, Neumeister P and Pichler M: MicroRNAs in diffuse large B-cell lymphoma: Implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 34: 557-564, 2014.

28. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N and Isaacs WB: DAS: A test procedure for tissue-specific expression of non-coding RNAs in AR-mediated signaling. Nucleic Acid Res 26: e008, 2008.

29. Heemers HV and Tindall DJ: Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28: 778-808, 2007.

30. Chang CS, Kokontis J and Liao ST: Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240: 324-326, 1988.

31. Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004.

32. Jenzschik J, Zhag Y, Zhang A, Zengerling F, Damjanoski I and Cronauer MV: Androgen receptor aberrations in the era of abiraterone and enzalutamide. World J Urol 34: 297-303, 2016.

33. Mitsiades N: A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res 72: 3457-3462, 2012.

34. Abdel-Mageed AB, Sikka SC and Mondal D: Multimodal interactionâ€¢resistant prostate cancer. Cancer Res 72: 3457-3462, 2012.

35. Khurana N, Kim H, Chandra PK, Talwar S, Sharma P, Morgan TM, Koreckij TD and Corey E: Targeted therapy for prostate cancer: Implications for prostate cancer detection and progression. PLoS One 4: e4995, 2009.

36. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Sinkels DW and Schalken JA: D3(DPCA), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62: 2695-2698, 2002.

37. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ and Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225, 2003.

38. Yang Z, Yu L and Wang Z: PCA3 and TMPRSS2-ERG gene fusions as diagnostics biomarkers for prostate cancer. Clin J Cancer Res 28: 65-71, 2016.

39. Lemos AE, Ferreira LB, Batoreu NM, de Freitas PP, Bonamino MH and Gibma ER: PCA3 long non-coding RNA modulates the expression of key cancer-related genes in LNCaP prostate cancer cells. Tumour Biol 37: 4451-4462, 2016.

40. Morgan TM, Koreckij TD and Corey E: Targeted therapy for advanced prostate cancer: Inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9: 237-249, 2009.

41. Gao N, Zhang Y, Jiang BH and Shi X: Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 380: 342-431, 2012.

42. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC, Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W: Long non-coding RNA in prostate cancer. Curr Cancer Drug Targets 10: 247-249, 2009.

43. Xue M, Chen W and Li X: Urothelial cancer associated 1: A long non-coding RNA with a crucial role in cancer. J Cancer Res Clin Oncol 142: 1407-1419, 2016.
RNA biomarkers associated with metastasis by inducing epithelial-to-mesenchymal transition. Mol Oncotargets Th 10: 1843-1852, 2017.

Wang J, Cheng G, Li X, Pan Y, Qin C, Yang H, Hua L and Wang Z: Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer. Tumour Biol 37: 9603-9613, 2016.

Thorne H, Mitchell G and Fox S: kConFab: A familial breast cancer consortium facilitating research and translational oncology. J Natl Cancer Inst Monogr 2011: 79-81, 2011.

Du Z, Fei T, Verhaak RG, Su Z, Zhang Y, Brown M, Chen Y and Liu XS: Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol 20: 908-913, 2013.

Presnerr JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M, et al.: The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through c-Myc. Neoplasia 16: 900-908, 2014.

Presnerr JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhankasedaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, et al.: RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol 15: 1469-1480, 2014.

Mehra R, Udager AM, Ahearn T, Cao X, Feng FY, Loda M, Petimaro JS, Kantoff P, Mucci LA and Chinnaiyan AM: Overexpression of the long Non-coding RNA SChLAP1 independently predicts lethal prostate cancer. Eur Urol 70: 549-552, 2016.

Mehra R, Shi Y, Udager AM, Presnerr JR, Sahu A, Iyer MK, Siddiqui J, Cao X, Wei J, Jiang H, et al.: A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Neoplasia 16: 1121-1127, 2014.

Presnerr JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, et al.: The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWAT/SNF complex. Nat Genet 45: 1392-1398, 2013.

Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, Wei M, Shen J, Hou J, Gao X, et al.: Long noncoding RNA MALAT1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol 190: 2278-2287, 2013.

Viazzi F, Bonino B, Ratto E, Desideri G and Pontremoli R: Hyperuricemia, diabetes and hypertension. G Ital Nefrol 32 (Suppl 62): ginn32 S62.10, 2015 (In Italian).

Mei YH, Yu JP and Li G: An extramuralary plasmacytoma in the kidney of a 14-year-old girl: Case report and review of the literature. Medicine (Baltimore) 96: e6092, 2017.

Zhao Z, Chen C, Liu Y and Wu C: 17β-Estradiol treatment inhibits breast cell proliferation, migration and invasion by decreasing MALAT-1 RNA level. Biochem Biophys Res Commun 445: 388-393, 2016.

Ying L, Chen Q, Wang Y, Zhou Z, Huang Y and Qiu F: Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst 8: 2289-2294, 2012.

Hu L, Wu Y, Tan D, Meng H, Wang K, Bai Y and Yang K: Up-regulation of long non coding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res 34: 7, 2015.

Wang X, Li M, Wang Z, Han S, Tang X, Ge Y, Zhou L, Zhou C, Yuan Q and Yang M: Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. J Biol Chem 290: 3925-3935, 2015.

Hirata H, Hinoya Y, Shahrzadi V, Deng G, Nakajima K, Tabata ZL, Ishii N and Daihaya R: Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through EzH2 and interacts with miR-205. Cancer Res 75: 1322-1331, 2015.

Joaquim M and Watson RJ: Cell cycle regulation by the B-Myb transcription factor. Cell Mol Life Sci 60: 2389-2401, 2003.

Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng R, Wang Y, Huang J, Xu M, Yan J and Yu J: IncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. FEBS J 281: 3766-3775, 2014.

Presnerr JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, et al.: PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 74: 1651-1660, 2014.

Gary Z, Zeevi DA, Renbaum P, Zeligson S, Eini L, Bashari D, Smith Y, Labad A, Goldberg M, Ginsberg D and Levy-Lahad E: TORDA, an IncRNA at the RAD51 locus, is oppositely regulated to RAD51, and enhances RAD51-dependent DSB (Double Strand Break) repair. PLoS One 10: e0134120, 2015.

Tay Y, Rinn J and Pandolfi PP: The multilayered complexity of ceRNA crosstalk and competition. Nature 505: 344-352, 2014.

Jalali S, Bhartiya D, Lalwani MK, Sivasubbu S and Scaria V: Systematic transcriptome wide analysis of IncRNA-miRNA interactions. PLoS One 8: e53823, 2013.

Chiyomura T, Yamamura S, Fukuthara S, Yoshino H, Kinoshita T, Majid S, Sainsi S, Chang I, Tanaka Y, Enokida H, et al.: Genestin inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR. PLoS One 8: e07372, 2013.

Salehi S, Taherini MN, Azarpira N, Zare A and Behzad-Bebahani A: State of the art technologies to explore long non-coding RNAs in cancer. J Cell Mol Med 21: 3120-3140, 2017.

Tsai MC, Spitale RC and Chang HY: Long intergenic noncoding RNAs: New links in cancer progression. Cancer Res 71: 3-7, 2011.

Shechner DM, Hacisuleyman E, Younger ST and Rinn JL: Multiplexable, locus-specific targeting of long RNAs with CRISPR-display. Nat Methods 12: 664-670, 2015.

St Laurent G, Wåhlestedt C and Karpovan P: The Landscape of long noncoding RNA classification. Trends Genet 31: 239-251, 2015.